Scinopharm TaiwanTPE:1789 -2.68%76 OCF Margin % is 34.12% as of Dec. 2025, which is 34% above its 10-year median of 25.49. GuruFocus rates TPE:1789 with a GF Score™ of 76/100 and a GF Value™ of NT$27.02 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 956 Drug Manufacturers companies, Scinopharm Taiwan ranks better than 75% on this metric.
The historical rank and industry rank for Scinopharm Taiwan's OCF Margin % or its related term are showing as below:
TPE:1789'
s OCF Margin % Range Over the Past 10 Years
Min: 7.25 Med: 25.49 Max: 41.31
Current: 18.84
During the past 13 years, the highest OCF Margin % of Scinopharm Taiwan was 41.31%. The lowest was 7.25%. And the median was 25.49%.
TPE:1789's OCF Margin % is ranked better than 75% of 956
companies
in the Drug Manufacturers industry
Industry Median: 9.985
vs TPE:1789: 18.84
Scinopharm Taiwan OCF Margin % Related Terms
Scinopharm Taiwan OCF Margin % Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan (TPE:1789) has a OCF Margin % of 34.12% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Scinopharm Taiwan and its competitors. This is 34% above median its historical median of 25.49. Over the past decade, Scinopharm Taiwan's OCF Margin % has ranged from 7.25 to 41.31. According to the industry distribution chart, Scinopharm Taiwan ranks #239 out of 956 companies in the Drug Manufacturers industry, placing it in the top 25%.
Is Scinopharm Taiwan's OCF Margin % too high?
Scinopharm Taiwan's current OCF Margin % of 34.12% is 34% above median its 10-year median of 25.49. Over the past 10 years, this metric has ranged from a low of 7.25 to a high of 41.31. The Drug Manufacturers industry median OCF Margin % is 9.99. Scinopharm Taiwan's value of 34.12% is 241.7% above this industry median. Based on the distribution chart, Scinopharm Taiwan ranks #239 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Scinopharm Taiwan has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Scinopharm Taiwan ranks #239 out of 956 companies for OCF Margin %. This places Scinopharm Taiwan in the top 25% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.99. Scinopharm Taiwan's value of 34.12% is 241.7% above this benchmark. Historically, Scinopharm Taiwan's own OCF Margin % has ranged from 7.25 to 41.31 over the past decade. While the company's 10-year median is 25.49 vs. the industry median of 9.99, Scinopharm Taiwan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.99, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scinopharm Taiwan's current OCF Margin % of 34.12% is 241.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Scinopharm Taiwan and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinopharm Taiwan's current OCF Margin % is 34.12%, which is 34% above median its own 10-year median of 25.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.02, compared to a current price of NT$20.00 — trading 26% below its estimated fair value. The current OCF Margin % is 34.12%, which is 34% above median its 10-year median of 25.49 and 241.7% above the Drug Manufacturers industry median of 9.99. Scinopharm Taiwan's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current OCF Margin % is 34.12% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$20.00 is trading 26% below its estimated GF Value™ of NT$27.02.
GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.
Key valuation signals for TPE:1789:
OCF Margin %: 34.12% (34% above median its 10-year median of 25.49)
GF Value™: NT$27.02 vs. price of NT$20.00 (26% below fair value)
Industry Position: 241.7% above the Drug Manufacturers median (#239 of 956)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
76GF Score
Get the complete analysis for TPE:1789
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
